


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (Currently amended) A compound of formula (I)



including enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts, thereof wherein:

A, B, D, and E, are selected from N or C, ~~J and K are C, X and Y are both N, and exactly one of A, B, D, and E is N;~~

~~L is selected from O, NH and S, wherein L may be connected to any one of A, B, D, E, J, X, K, or Y;~~

M is CH or N;

P is a bond or C=O, wherein P is connected to any one of J, X, K, or Y;

Z is C(=O)GR² or C(H)₂GR²; ~~GT¹T²-G-R² where T¹ and T² are independently selected from H, alkyl or substituted alkyl or T¹ and T² are taken together to form O, and~~

G is alkyl, O or NH or none, or when Z is C(=O)GR², G also includes 1, 2 propylene;

n is 0-4;

R¹ is selected from halogen, -CN, -CF₃, substituted alkyl, aryl, and heteroaryl;

R² is a 5- to 6-membered heterocycloalkyl containing at least one N; and

~~R³ is selected from halogen, cyano, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl, wherein R³ is connected to any one of A, B, D, and E;~~

R⁴ and R⁵ are H;

or R⁴ and R⁵ may be taken together with the atoms to which they are attached to form a ring wherein the ring is selected from piperidine and piperazine; and

R¹⁰ is selected from H, alkyl, substituted alkyl, alkenyl, and substituted alkenyl.

2. (Currently amended) A compound of claim 1 including enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts, thereof wherein:

A is N;

B, D, and E are CH;

~~either of X or Y or both are N;~~

~~L is NH;~~

M is N;

~~n is 1;~~

n is 2;

R¹ is selected from halogen, -CN, -CF₃, substituted alkyl, aryl, and heteroaryl; and


R² is a piperidine or pyrrolidine ring ~~heterocycloalkyl containing at least one N;~~ and



~~R¹⁰ is H.~~

3. (Canceled)


4. (Canceled)

5. (Previously presented) A compound of claim 2 including enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts, thereof selected from:





and



6. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
7. (Canceled).
8. (Previously presented) A method for the treatment of asthma comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim [2]6, wherein the compound of the pharmaceutical composition is an antagonist.
9. (Previously presented) A method for the treatment of rheumatoid arthritis comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim [2]6, wherein the compound of the pharmaceutical composition is an antagonist.
10. (Previously presented) A method for the treatment of psoriasis comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim [2]6, wherein the compound of the pharmaceutical composition is an antagonist.
11. (Previously presented) A method for the treatment or prevention of solid organ transplant rejection comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim [2]6, wherein the compound of the pharmaceutical composition is an antagonist.
12. (Currently amended) A method for the treatment of chronic ~~obstructure~~ obstructive pulmonary disease comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim [2]6, wherein the compound of the pharmaceutical composition is an antagonist.